Clinical significance of anti-citrullinated peptide antibody in Japanese patients with established rheumatoid arthritis [1]

Scandinavian Journal of Rheumatology

Volumn 34, Issue 6, 2005, Pages 489-490

  Nakamura, H ^a   Kawakami, A ^a   Ida, H ^a   Origuchi, T ^a   Matsuoka, N ^b   Tsuboi, M ^a   Furuyama, M ^c   Mizokami, A ^d   Tsukada, T ^e   Nakashima, M ^f   Ejima, E ^a   Hamasaki, K ^a   Aoyagi, K ^g   Uetani, M ^h   Fukuda, T ⁱ   Honda, S ⁱ   Urayama, S ^j   Kawabe, Y ^j   Ueki, Y ^k   Mine, M ^l   Eguchi, K ^a   more..

^a NAGASAKI UNIVERSITY   (Japan)

^b Gotokai Hospital   (Japan)

^c Nagasaki City Hospital   (Japan)

^d Nagasaki Citizen Hospital   (Japan)

^e NAGASAKI ROSAI HOSPITAL   (Japan)

^f Japanese Red Cross Nagasaki Atomic Bomb Hospital Nagasaki   (Japan)

^g HIROSHIMA UNIVERSITY   (Japan)

^h Graduate School of Biomedical Sciences   (Japan)

ⁱ KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j Ureshino Medical Center   (Japan)

^k Sasebo City General Hospital   (Japan)

^l Isahaya Insurance General Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; STROMELYSIN;

ANTIBODY DETECTION; ANTIBODY TITER; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; INTERMETHOD COMPARISON; LETTER; MAJOR CLINICAL STUDY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SJOEGREN SYNDROME; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; JAPAN; MATRIX METALLOPROTEINASES; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 30344486566     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740510026706     Document Type: Letter

References (8)

1. Dubucquoi S, Solau-Gervais E, Lefranc D, Marguerie L, Sibilia J, Goetz J, et al. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 2004;63:415-9.
2. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995;95:2672-9.
3. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
4. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
5. Suzuki K, Sawada T, Murakami A, Matsui T, Tohma S, Nakazono K, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003;32:197-204.
6. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
7. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427-30.
8. Yamanaka H, Matsuda Y, Tanaka M. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43:852-8.